13F Holdings
中文EN

ABSI Absci Corp

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1672688 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-47.2%
TTM net income YoY-9.7%
TTM EPS YoY13.2%
Revenue 3-yr CAGR-40.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,812.3%
Net margin-8,451.3%
FCF margin-7,562.7%
EBITDA margin-8,076.6%

Returns

ROE-58.6%
ROA-51.9%
ROIC (approx.)-53.3%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio9.64x
Interest coverage-2,569.39x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue-4.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.80M$4.53M$5.72M$5.75M$4.78M
R&D expense$81.42M$63.86M$48.07M$58.91M$44.59M
SG&A expense$35.06M$36.17M$37.83M$40.55M$28.78M
Operating income-$120.32M-$108.89M-$115.52M-$106.75M-$75.24M
Interest expense$209,000$565,000$1.01M$972,000$3.43M
Pretax income-$115.11M-$103.04M-$110.47M-$105.36M-$109.86M
Income tax$69,000$70,000$100,000-$461,000-$8.90M
Net income-$115.18M-$103.11M-$110.57M-$104.90M-$100.96M
EBITDA-$108.58M-$95.50M-$101.52M-$93.71M-$68.58M
EPS (basic)-0.84-0.94-1.20-1.15-2.08
EPS (diluted)-0.84-0.94-1.20-1.15-2.08
Weighted avg. shares (diluted)136.78M110.24M92.03M90.85M49.69M
Balance sheet
Cash & equivalents$20.02M$58.21M$89.67M$76.84M$279.93M
Short-term investments$124.27M$71.21M——$0
Receivables—$0$2.19M——
Current assets$149.57M$133.83M$120.58M$186.86M$273.08M
PP&E, net$20.86M$29.17M$41.33M$52.72M$52.11M
Goodwill——$0$21.34M$21.34M
Intangibles$41.51M$44.88M$48.25M$51.62M$54.99M
Total assets$216.30M$213.61M$217.30M$321.01M$426.19M
Current liabilities$22.77M$28.66M$29.56M$30.27M$33.86M
Long-term debt—$3.99M$7.92M$10.93M$3.52M
Total debt—$3.99M$7.92M$10.93M$3.52M
Total liabilities$26.85M$34.48M$41.12M$46.59M$60.09M
Shareholders' equity$189.45M$179.13M$176.18M$274.41M$366.11M
Net debt—-$54.22M-$81.75M-$65.91M-$276.40M
Shares outstanding—115.36M93.09M92.41M92.65M
Cash flow statement
Operating cash flow-$92.92M-$72.40M-$64.64M-$81.34M-$60.60M
Capital expenditure$1.11M$404,000$860,000$16.18M$38.05M
Free cash flow-$94.03M-$72.81M-$65.50M-$97.51M-$98.64M
Investing cash flow-$50.16M-$41.58M$81.94M-$126.98M-$67.38M
Financing cash flow$105.95M$82.53M-$4.48M$5.24M$336.19M
Depreciation & amortization$11.74M$13.39M$14.00M$13.04M$6.65M
Stock-based compensation$18.32M$19.45M$11.42M$12.54M$10.61M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.